Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $500000.0 for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 10.39% year-over-year to $500000.0; the TTM figure through Mar 2026 stood at $500000.0 (down 10.39% YoY), while the FY2025 annual figure was $500000.0, down 41.11% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $500000.0, roughly flat from $500000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $45.0 million in Q1 2022, with the low at $500000.0 in Q2 2023.
• The 5-year median for Other Non-Current Liabilities is $996000.0 (2024), against an average of $4.0 million.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 10168.95% in 2022, then plunged 96.02% in 2023.
• Zentalis Pharmaceuticals' Other Non-Current Liabilities stood at $2.6 million in 2022, then plunged by 32.06% to $1.8 million in 2023, then sank by 52.3% to $849000.0 in 2024, then plunged by 41.11% to $500000.0 in 2025, then changed by 0.0% to $500000.0 in 2026.
• Business Quant data shows ZNTL's Other Non-Current Liabilities at $500000.0 in Q1 2026, $500000.0 in Q4 2025, and $500000.0 in Q3 2025.